| 摘要 |
A pharmaceutical product comprising an SSRI and a non-sedating anxiolytic compound, which is a modulator of the benzodiazepine binding site of the human GABAA receptor, having a binding affinity for the alpha3 subunit of the human GABAA receptor of 10 nM or less, which elicits at least a 40% potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the alpha3 subunit of alpha3 and which elicits at most a 30% potentiation of the GABA EC20 response in stably transfected cell lines expressing the alpha1 subunit of the human GABAA receptor is disclosed for simultaneous, separate or sequential administration.
|
